BTG completes the acquisition of Galil Medical

BTG completes the acquisition of Galil Medical

BTG completes the acquisition of Galil Medical

London, UK: BTG plc (LSE: BTG), the specialist healthcare company, is pleased to announce that it has completed the acquisition of Galil Medical, a leading provider of cryoablation products for the treatment of kidney and other cancers.

BTG announced on 6 May 2016 that it had entered into an agreement to acquire Galil.

For further information contact:


BTG 
  
Andy Burrows, VP Corporate & Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605

Stuart Hunt, Investor Relations Manager
+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536

Chris Sampson, Corporate Communications Director
+44 20 7575 1595; Mobile: +44 7773 251 178

FTI Consulting
Ben Atwell/Simon Conway
+44 (0)20 3727 1000

Back to press releases
  • Partnering

    BTG welcomes new opportunities for licensing and acquisition. Our Business Development strategy is focused on opportunities that complement our current product portfolio, capabilities and overall growth strategy with a focus on late-stage development and marketed products.

    Read more
  • SEE MORE
    REACH FURTHER
    TREAT SMARTER

    BTG believes Interventional Medicine is the place to be. We are at the forefront today and committed to research that will keep us at the forefront tomorrow.

    btg-im.com